Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus PRESTALIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus PRESTALIA.
ACEON vs PRESTALIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
PRESTALIA is a fixed-dose combination of perindopril, an angiotensin-converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker. Perindopril inhibits ACE, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral resistance.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
One tablet orally once daily, preferably in the morning. PRESTALIA is a fixed-dose combination of perindopril arginine (2.5 mg, 5 mg, or 10 mg) and amlodipine (5 mg or 10 mg). Initial dose: 3.5 mg perindopril arginine/2.5 mg amlodipine or 5 mg perindopril arginine/5 mg amlodipine. Titrate based on blood pressure response. Maximum dose: 10 mg perindopril arginine/10 mg amlodipine.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Perindoprilat: 30–120 hours (terminal, prolonged in renal impairment; effective half-life for accumulation ~24h). Indapamide: 14–24 hours (terminal).
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Perindopril: 75% renal (as perindoprilat), 25% biliary/fecal. Indapamide: 70% renal, 20% biliary/fecal.
Category C
Category C
ACE Inhibitor
ACE Inhibitor/Calcium Channel Blocker Combination